| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J P Dahl, C Jepson, R Levenson, E P Wileyto, F Patterson, W H Berrettini, C Lerma. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. The pharmacogenomics journal. vol 6. issue 3. 2006-08-01. PMID:16402081. |
we have previously demonstrated that a functional dopamine d2 receptor promoter variant (drd2 -141 ins/del) predicts response to nicotine replacement therapy (nrt). |
2006-08-01 |
2023-08-12 |
human |
| J Fould. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. International journal of clinical practice. vol 60. issue 5. 2006-07-25. PMID:16700857. |
nicotine abstinence reduces dopamine release, and this is associated with withdrawal symptoms and craving for nicotine. |
2006-07-25 |
2023-08-12 |
Not clear |
| J Fould. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. International journal of clinical practice. vol 60. issue 5. 2006-07-25. PMID:16700857. |
varenicline, a specific alpha4beta2 nicotinic receptor partial agonist, is a new pharmacotherapy that stimulates dopamine and simultaneously blocks nicotine receptors. |
2006-07-25 |
2023-08-12 |
Not clear |
| Monica Mameli-Engvall, Alexis Evrard, Stéphanie Pons, Uwe Maskos, Torgny H Svensson, Jean-Pierre Changeux, Philippe Faur. Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron. vol 50. issue 6. 2006-07-25. PMID:16772172. |
nicotine elicits dopamine release by stimulating nicotinic acetylcholine receptors (nachrs) on dopaminergic neurons. |
2006-07-25 |
2023-08-12 |
mouse |
| Nina Lindblom, Sabina H L de Villiers, Svetlana Semenova, Genadiy Kalayanov, Sandra Gordon, Björn Schilström, Anette M Johansson, Athina Markou, Torgny H Svensso. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn-Schmiedeberg's archives of pharmacology. vol 372. issue 3. 2006-07-20. PMID:16292514. |
active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. |
2006-07-20 |
2023-08-12 |
rat |
| Nina Lindblom, Sabina H L de Villiers, Svetlana Semenova, Genadiy Kalayanov, Sandra Gordon, Björn Schilström, Anette M Johansson, Athina Markou, Torgny H Svensso. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn-Schmiedeberg's archives of pharmacology. vol 372. issue 3. 2006-07-20. PMID:16292514. |
we recently showed that active immunisation with the nicotine immunoconjugate ip18-klh reduces the nicotine-induced increase in dopamine (da) output in the nucleus accumbens (nac) and prevents reinstatement of nicotine-seeking behaviour in rats. |
2006-07-20 |
2023-08-12 |
rat |
| Kent Jardemark, Monica M Marcus, Asa Konradsson, Torgny H Svensso. The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. The international journal of neuropsychopharmacology. vol 8. issue 2. 2006-07-19. PMID:15469665. |
here, we tested whether nicotine, which facilitates dopamine release, also facilitates nmda receptor-mediated neurotransmission in the mpfc, when given alone or in combination with a d(2,3) antagonist, raclopride, or a d4 antagonist, 3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1h-pyrrolo[2,3b]pyridine (l-745,870), using intracellular recording in pyramidal cells of the rat mpfc. |
2006-07-19 |
2023-08-12 |
rat |
| J R Pauly, C M Charriez, M V Guseva, S W Schef. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Annals of the New York Academy of Sciences. vol 1035. 2006-07-13. PMID:15681815. |
the actions of nicotine on dopamine release may explain the variable effects of nicotine in animal models of parkinson's and huntington's diseases. |
2006-07-13 |
2023-08-12 |
mouse |
| Helen L Alderson, Mary P Latimer, Philip Win. Intravenous self-administration of nicotine is altered by lesions of the posterior, but not anterior, pedunculopontine tegmental nucleus. The European journal of neuroscience. vol 23. issue 8. 2006-07-13. PMID:16630063. |
the reinforcing properties of nicotine involve actions at nicotinic acetylcholine receptors located on dopamine (da) neurons in the ventral tegmental area (vta). |
2006-07-13 |
2023-08-12 |
rat |
| Johanna Krause, Klaus-Henning Krause, Stefan H Dresel, Christian la Fougere, Manfred Ackenhei. ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. Dialogues in clinical neuroscience. vol 8. issue 1. 2006-06-28. PMID:16640111. |
adhd in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. |
2006-06-28 |
2023-08-12 |
Not clear |
| Jacques Cornu. Treating tobacco use and dependence in clinical practice. Expert opinion on pharmacotherapy. vol 7. issue 6. 2006-06-27. PMID:16556092. |
for smokers who are ready to quit, the physician should show strong support, help set a date to quit, prescribe pharmaceutical therapies for nicotine dependence, such as nicotine replacement therapy (i.e., gum, transdermal patch, nasal spray, mouth inhaler, lozenges, and micro and sublingual tablets) and/or bupropion (an atypical antidepressant thought to work by blocking the neural re-uptake of dopamine and/or noradrenaline), with instructions for use, and suggest behavioural strategies to prevent relapse. |
2006-06-27 |
2023-08-12 |
Not clear |
| Jukka S Pakkanen, Jan Stenfors, Eija Jokitalo, Raimo K Tuomine. Effect of chronic nicotine treatment on localization of neuronal nicotinic acetylcholine receptors at cellular level. Synapse (New York, N.Y.). vol 59. issue 7. 2006-06-16. PMID:16485261. |
chronic nicotine treatment increased clustering of nachrs, which could have a role in the release of dopamine (da) evoked by nicotine. |
2006-06-16 |
2023-08-12 |
mouse |
| Karl Fagerström, David J K Balfou. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert opinion on investigational drugs. vol 15. issue 2. 2006-06-12. PMID:16433591. |
preclinically, this drug mimics the effects of nicotine on dopamine (da) release in the nucleus accumbens when given alone but attenuates this response to a subsequent nicotine challenge and reduces nicotine self administration. |
2006-06-12 |
2023-08-12 |
Not clear |
| Russell W Brown, Marla K Perna, Tori L Schaefer, Michael T William. The effects of adulthood nicotine treatment on D2-mediated behavior and neurotrophins of rats neonatally treated with quinpirole. Synapse (New York, N.Y.). vol 59. issue 5. 2006-05-25. PMID:16408261. |
animals were neonatally treated with quinpirole, a dopamine (da) d2/d3 agonist, from postnatal day 1-21 (p1-21) and raised to p60 and administered nicotine tartarate (0.3 mg/kg free base) or saline twice daily for 14 days. |
2006-05-25 |
2023-08-12 |
mouse |
| Maryka Quik, Li Chen, Neeraja Parameswaran, Xinmin Xie, J William Langston, Sarah E McCallu. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 17. 2006-05-23. PMID:16641249. |
to identify the cellular changes associated with this protective action, we investigated the effects of nicotine treatment on stimulus-evoked dopamine release, dopamine turnover, and synaptic plasticity in striatum from lesioned and unlesioned animals. |
2006-05-23 |
2023-08-12 |
monkey |
| Maryka Quik, Li Chen, Neeraja Parameswaran, Xinmin Xie, J William Langston, Sarah E McCallu. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 17. 2006-05-23. PMID:16641249. |
in contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. |
2006-05-23 |
2023-08-12 |
monkey |
| Maryka Quik, Li Chen, Neeraja Parameswaran, Xinmin Xie, J William Langston, Sarah E McCallu. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 17. 2006-05-23. PMID:16641249. |
long-term nicotine administration also attenuated the enhanced k(+)-evoked fractional dopamine release from synaptosomes of mptp-lesioned animals, suggesting that nicotine treatment had a generalized effect on dopaminergic function. |
2006-05-23 |
2023-08-12 |
monkey |
| Maryka Quik, Li Chen, Neeraja Parameswaran, Xinmin Xie, J William Langston, Sarah E McCallu. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 17. 2006-05-23. PMID:16641249. |
this premise was further supported by experiments showing that nicotine dosing decreased the elevated dopamine turnover that occurs after nigrostriatal damage. |
2006-05-23 |
2023-08-12 |
monkey |
| Caryn Lerman, Christopher Jepson, E Paul Wileyto, Leonard H Epstein, Margaret Rukstalis, Freda Patterson, Vyga Kaufmann, Stephanie Restine, Larry Hawk, Ray Niaura, Wade Berrettin. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 1. 2006-05-12. PMID:16123753. |
role of functional genetic variation in the dopamine d2 receptor (drd2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. |
2006-05-12 |
2023-08-12 |
human |
| Caryn Lerman, Christopher Jepson, E Paul Wileyto, Leonard H Epstein, Margaret Rukstalis, Freda Patterson, Vyga Kaufmann, Stephanie Restine, Larry Hawk, Ray Niaura, Wade Berrettin. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 1. 2006-05-12. PMID:16123753. |
we investigated the roles of two functional genetic variants in the dopamine d2 receptor (drd2) gene in response to pharmacotherapy for tobacco dependence among participants in two randomized clinical trials with a 6-month follow-up period: a double-blind placebo-controlled trial of bupropion (n=414) and an open label trial of transdermal nicotine vs nicotine nasal spray (n=368). |
2006-05-12 |
2023-08-12 |
human |